Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,netReceivables,inventory,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,changeToNetincome,capitalExpenditures,otherCashflowsFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,currency,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,exchange,exchangeDataDelayedBy,marketState,twoHundredDayAverageChangePercent,shortName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,market,priceHint,regularMarketChangePercent,regularMarketDayRange,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Aug 12, 2021) 4","Short Ratio (Aug 12, 2021) 4","Short % of Float (Aug 12, 2021) 4","Short % of Shares Outstanding (Aug 12, 2021) 4","Shares Short (prior month Jul 14, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry,address2
t0,DMTK,267309000.0,28938700,3594000,,-17102000,,-17102000,14208000,495000,-17307000,-17307000,,,,,,0,3119000,20426000,2624000,205000,,-17102000,-17102000,427503000.0,8391000.0,267309000.0,1626000.0,275700000.0,3000.0,134000.0,-160199000.0,579000.0,2000.0,167000.0,229609000.0,7642000.0,2000.0,3285000.0,272248000.0,38644000.0,2185000.0,497000.0,2104000.0,754000.0,1156000.0,-178000.0,-26000.0,24003000.0,-92000.0,24029000.0,11014000.0,-12811000.0,208000.0,-218000.0,-331000.0,3568000.0,-932000.0,,264606000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,37.2,36.61,36.92,10,10,finmb_732221,NasdaqCM,"DermTech, Inc.",USD,715890,368366,26.824,2.7229722,9.851 - 84.49,-47.815,-0.56592494,9.851,84.49,1567123200,1620936000,1620936000,1620936000,-3.343,-1.89,-2.46,-14.908536,1.579,34.828888,1.8461113,0.053005174,43.830074,-7.155075,1061326784,-19.404762,23.226725,15,America/New_York,EDT,-14400000,False,False,NCM,0,REGULAR,-0.16324578,"DermTech, Inc.",36.675,1630505290,-0.5250015,37.2,37.69,36.4,52646,us_market,2,-1.4112943,36.4 - 37.69,,,,84.49,9.85,34.83,43.83,715.89k,368.37k,28.94M,,18.81M,9.68%,73.36%,4.49M,7.03,18.47%,15.17%,5.09M,,,,,,0.00%,"Aug 29, 2019",,1:2,"Aug 29, 2019","Dec 30, 2020","Jun 29, 2021",0.00%,-532.16%,-17.84%,-31.22%,9.13M,0.38,269.50%,-96k,-47.83M,-50.92M,-3.34,,268.25M,9.06,282k,0.10,35.62,1.58,-38.43M,-22.53M,Value,92037,Healthcare,114,9,9,"DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.",La Jolla,858 450 4222,CA,8,1609372800,1625097600,8,United States,http://www.dermtech.com,86400,9,11099 North Torrey Pines Road,858 200 3877,Diagnostics & Research,Suite 100
t-1,DMTK,256827000.0,28938700,2251000,,-15068000,,-15068000,11684000,522000,-13413000,-13413000,,,,,,0,2524000,15937000,2002000,-1655000,,-15068000,-15068000,399913000.0,8198000.0,256827000.0,1636000.0,265025000.0,3000.0,339000.0,-143097000.0,903000.0,8000.0,167000.0,218595000.0,7097000.0,8000.0,3124000.0,261734000.0,39603000.0,1854000.0,279000.0,2621000.0,-203000.0,443000.0,-215000.0,-27000.0,205278000.0,254000.0,205305000.0,194347000.0,-10716000.0,193000.0,-175000.0,-374000.0,4011000.0,-12000.0,,254637000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,37.2,36.61,36.92,10,10,finmb_732221,NasdaqCM,"DermTech, Inc.",USD,715890,368366,26.824,2.7229722,9.851 - 84.49,-47.815,-0.56592494,9.851,84.49,1567123200,1620936000,1620936000,1620936000,-3.343,-1.89,-2.46,-14.908536,1.579,34.828888,1.8461113,0.053005174,43.830074,-7.155075,1061326784,-19.404762,23.226725,15,America/New_York,EDT,-14400000,False,False,NCM,0,REGULAR,-0.16324578,"DermTech, Inc.",36.675,1630505290,-0.5250015,37.2,37.69,36.4,52646,us_market,2,-1.4112943,36.4 - 37.69,,,,84.49,9.85,34.83,43.83,715.89k,368.37k,28.94M,,18.81M,9.68%,73.36%,4.49M,7.03,18.47%,15.17%,5.09M,,,,,,0.00%,"Aug 29, 2019",,1:2,"Aug 29, 2019","Dec 30, 2020","Jun 29, 2021",0.00%,-532.16%,-17.84%,-31.22%,9.13M,0.38,269.50%,-96k,-47.83M,-50.92M,-3.34,,268.25M,9.06,282k,0.10,35.62,1.58,-38.43M,-22.53M,Value,92037,Healthcare,114,9,9,"DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.",La Jolla,858 450 4222,CA,8,1609372800,1625097600,8,United States,http://www.dermtech.com,86400,9,11099 North Torrey Pines Road,858 200 3877,Diagnostics & Research,Suite 100
t-2,DMTK,63490000.0,28938700,1913000,,-9443000,,-9443000,7936000,396000,-9453000,-9453000,,,,,,0,2121000,11574000,1725000,10000,,-9443000,-9443000,189849000.0,6290000.0,63490000.0,1205000.0,69780000.0,2000.0,135000.0,-126360000.0,639000.0,-1000.0,167000.0,24248000.0,5425000.0,-1000.0,2731000.0,66882000.0,39529000.0,1480000.0,104000.0,1573000.0,-2600000.0,1045000.0,-2857000.0,-9000.0,19227000.0,492000.0,19236000.0,9623000.0,-6747000.0,180000.0,11000.0,-473000.0,1441000.0,-257000.0,,61457000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,37.2,36.61,36.92,10,10,finmb_732221,NasdaqCM,"DermTech, Inc.",USD,715890,368366,26.824,2.7229722,9.851 - 84.49,-47.815,-0.56592494,9.851,84.49,1567123200,1620936000,1620936000,1620936000,-3.343,-1.89,-2.46,-14.908536,1.579,34.828888,1.8461113,0.053005174,43.830074,-7.155075,1061326784,-19.404762,23.226725,15,America/New_York,EDT,-14400000,False,False,NCM,0,REGULAR,-0.16324578,"DermTech, Inc.",36.675,1630505290,-0.5250015,37.2,37.69,36.4,52646,us_market,2,-1.4112943,36.4 - 37.69,,,,84.49,9.85,34.83,43.83,715.89k,368.37k,28.94M,,18.81M,9.68%,73.36%,4.49M,7.03,18.47%,15.17%,5.09M,,,,,,0.00%,"Aug 29, 2019",,1:2,"Aug 29, 2019","Dec 30, 2020","Jun 29, 2021",0.00%,-532.16%,-17.84%,-31.22%,9.13M,0.38,269.50%,-96k,-47.83M,-50.92M,-3.34,,268.25M,9.06,282k,0.10,35.62,1.58,-38.43M,-22.53M,Value,92037,Healthcare,114,9,9,"DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.",La Jolla,858 450 4222,CA,8,1609372800,1625097600,8,United States,http://www.dermtech.com,86400,9,11099 North Torrey Pines Road,858 200 3877,Diagnostics & Research,Suite 100
t-3,DMTK,52248000.0,28938700,1618000,,-9388000,,-9388000,7533000,-246000,-9397000,-9397000,,,,,,0,1362000,10759000,1608000,9000,,-9388000,-9388000,169163000.0,4777000.0,52248000.0,1297000.0,57025000.0,2000.0,214000.0,-116917000.0,679000.0,,167000.0,14625000.0,4098000.0,,2324000.0,54534000.0,36906000.0,1007000.0,115000.0,819000.0,-36906000.0,494000.0,-37282000.0,-9000.0,-1038000.0,-477000.0,325000.0,-46477000.0,-8157000.0,158000.0,-32000.0,-285000.0,1373000.0,-376000.0,-1363000.0,50436000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,37.2,36.61,36.92,10,10,finmb_732221,NasdaqCM,"DermTech, Inc.",USD,715890,368366,26.824,2.7229722,9.851 - 84.49,-47.815,-0.56592494,9.851,84.49,1567123200,1620936000,1620936000,1620936000,-3.343,-1.89,-2.46,-14.908536,1.579,34.828888,1.8461113,0.053005174,43.830074,-7.155075,1061326784,-19.404762,23.226725,15,America/New_York,EDT,-14400000,False,False,NCM,0,REGULAR,-0.16324578,"DermTech, Inc.",36.675,1630505290,-0.5250015,37.2,37.69,36.4,52646,us_market,2,-1.4112943,36.4 - 37.69,,,,84.49,9.85,34.83,43.83,715.89k,368.37k,28.94M,,18.81M,9.68%,73.36%,4.49M,7.03,18.47%,15.17%,5.09M,,,,,,0.00%,"Aug 29, 2019",,1:2,"Aug 29, 2019","Dec 30, 2020","Jun 29, 2021",0.00%,-532.16%,-17.84%,-31.22%,9.13M,0.38,269.50%,-96k,-47.83M,-50.92M,-3.34,,268.25M,9.06,282k,0.10,35.62,1.58,-38.43M,-22.53M,Value,92037,Healthcare,114,9,9,"DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.",La Jolla,858 450 4222,CA,8,1609372800,1625097600,8,United States,http://www.dermtech.com,86400,9,11099 North Torrey Pines Road,858 200 3877,Diagnostics & Research,Suite 100
